Psoriatic Arthritis
Latest News
Study links air pollution to psoriasis flares
The findings underscore the need for clinicians to “consider environmental/external triggers in patients with chronic inflammatory diseases...
From the Journals
CV risk biomarkers tentatively identified in psoriatic disease
Troponin I and NT-proBNP levels were linked to cardiovascular risk independently of the Framingham Risk Score.
From the Journals
Drug survival study looks at what lasts longest in RA, axSpA, PsA, and psoriasis
Survival rates were highest for rituximab in rheumatoid arthritis and golimumab in axial spondyloarthritis in a study of two Danish registries.
From the Journals
Methotrexate plus leflunomide proves effective for PsA
The combination therapy outperformed methotrexate monotherapy as a treatment option for patients with psoriatic arthritis (PsA), though it did...
Guidelines
Updated perioperative guidance says when to hold antirheumatics
Rheumatologists and orthopedic surgeons revise advice on JAK inhibitors and add new medications.
From the Journals
One-third of psoriatic arthritis patients could have metabolic syndrome, data analysis finds
The results highlight the need for proper assessment of body weight and cardiovascular risk factors in patients with PsA at the onset of disease...
Conference Coverage
Patients are interrupting DMARD use well into the COVID-19 pandemic
Rates of patients stopping disease-modifying antirheumatic drugs (DMARDs) have begun to rise after initially falling during the pandemic, with...
Commentary
Dietary recommendations for inflammatory rheumatic diseases
France’s first set of dietary recommendations for chronic inflammatory rheumatic diseases are a welcome guide for health care professionals and...
Conference Coverage
Guselkumab controls axial involvement in PsA through 2 years
In psoriatic arthritis patients with axial involvement, researchers saw sustained improvement with guselkumab through 100 weeks on all outcomes...
Latest News
How to make the most of your time with psoriasis patients
Patients have a long-term battle to get clear, and spending a little longer on the initial visit “pays a lot of dividends.”
News from the FDA/CDC
FDA approves risankizumab (Skyrizi) for psoriatic arthritis
The approval is the second indication for the anti–interleukin-23 monoclonal antibody after clearance for plaque psoriasis was granted in 2019.